CoagulopathyNCT05874843
Validation of Point-of-care Thromboelastography (TEG 6s) in Pediatric Patients
A study testing Thromboelastography (TEG 6S) in people with Coagulopathy, run by Indiana University at 1 site in United States.
Trial summary
The goal of this observational study is to learn about the performance of the TEG6s in normal pediatric patients. The main questions it aims to answer are: What are the normal TEG 6S lab results in normal pediatric patients and how do they compare to existing published reference ranges. Read more about this study
- Who is it for?
- Ages 3 months to 18 years
- Conditions the study is for
- Coagulopathy
- What is being tested?
- Thromboelastography (TEG 6S)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 125 participants
- Where
- 1 siteUnited States
- Study dates
- 11 Sep 2023to 31 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 3 months to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- -Patients less than 18 years of age undergoing elective pediatric surgical care in the operating room at Riley Hospital for Children
Who cannot join
- Known disorder of coagulation pathway(s)
- Administration of medications that may alter the coagulation cascade
- Patients in foster care or wards of the court
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Riley Hospital for Children
Indianapolis, Indiana, 46202
Matthew Landman, MD, 317-944-4681, landman@iu.edu
About this study
The goal of this observational study is to learn about the performance of the TEG6s in normal pediatric patients. The main questions it aims to answer are: What are the normal TEG 6S lab results in normal pediatric patients and how do they compare to existing published reference ranges. Participants and their guardians will be asked to submit a small amount of blood at the beginning of an elective operation for analysis in the TEG 6s machine.
Read the detailed description
Trauma is the leading cause of death in children. Researchers, starting with Trunkey et al., have described three general time points of mortality after trauma - in the field, early secondary to hemorrhage and late due to infectious complications. Early mortality after trauma is specifically linked to hemorrhage. Trauma-induced coagulopathy is a multifactorial phenomenon present after trauma in both children and adults that can worsen hemorrhage and ultimately lead to increased mortality. Classical laboratory measurements of the coagulation pathway (PT, PTT, INR, fibrinogen, platelet count) have shown derangement after trauma and are correlated with mortality. However, these traditional tests of coagulation function take time to run as they are drawn and sent to a laboratory for evaluation and therefore provide a delayed snapshot of a potentially evolving coagulopathy scenario. Adult trauma centers have increasingly incorporated viscoelastic measures of the coagulation cascade to evaluate for and subsequently treat trauma-induced coagulopathy. One such test is thromboelastography (TEG) which is a whole blood assay that assesses functional clot kinetics and stability. It provides information on how various hemostatic factors, including coagulation factors, platelets, and fibrinogen, contribute to the clot. A 2016 randomized-controlled trial in adult trauma patients who met criteria for the institutions massive transfusion protocol were randomized to transfusion guided by TEG or by conventional measure of coagulopathy. The authors found increased survival in the TEG group as well as less transfusion of platelets and fresh frozen plasma.
TEG assesses the clot rate, clot strength, and clot stability, which then assists the clinician in choosing appropriate blood component therapy. The American College of Surgeons Trauma Quality Improvement Program recommends the use of thromboelastography when patients are at risk for trauma-induced coagulopathy. Visicoeslastic evaluation of the coagulation pathway has become the standard of care in adult trauma patients to provide information on a patient's coagulation status, particularly when the patient is requiring multiple blood products. This allows the physician to deliver a targeted hemostatic resuscitation appropriate for the patient needs in real-time. This can result in a decrease of blood products and quicker reversal of the trauma induced coagulopathy.
Riley Hospital for Children at IU Health has a TEG 5000 machine (Haemonetics Corp.) which performs the coagulation tests needed to help guide the resuscitation of a critical trauma patient. While an improvement over previous tests (such as INR, platelet count, PTT), the TEG 5000 still takes 45-60 minutes to get the results needed to guide fluid/blood resuscitation, making the results outdated as the patient has potentially received multiple units of blood products and/or had additional bleeding during that time. The TEG 5000 machine also has very specific environmental, and preparation needs (i.e. flat surface which is not bumped; controlled pipetting (dropping) of blood products into machine as well as mixing of reagents) that is very difficult to do in a busy trauma bay/emergency department with a critical patient.
The TEG 6s assays are performed in a microfluidic cartridge which only requires a small amount of a patient's blood be transferred to the cartridge for analysis. The vibration frequency of the blood meniscus at which resonance occurs is used to create a clot dynamics tracing. The sample is drawn automatically into the testing chambers rather than requiring manual pipetting, leading to less user variability. This simpler operation provides results in 15-20 minutes, making the test more clinically useful in guiding transfusion therapy during active bleeding.
TEG 6s and TEG 5000 have been evaluated in adult patients with good agreement between the modalities. More specifically, the TEG 6s has been validated in adult trauma patients. However, few pediatric studies exist.
- Conditions
- Coagulopathy
- Being tested
- Thromboelastography (TEG 6S)
- Keywords
- thromboelastography
- Medical subject headings
- Hemostatic Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Thromboelastography (TEG 6S)Diagnostic test
The TEG 6s assays are performed in a microfluidic cartridge which only requires a small amount of a patient's blood be transferred to the cartridge for analysis. The vibration frequency of the blood meniscus at which resonance occurs is used to create a clot dynamics tracing.
| Study group | Role | What they receive |
|---|---|---|
| Pediatric Participants | Other | Pediatric surgery patients undergoing elective pediatric surgical cases under anesthesia will be invited to participate in this prospective laboratory test validation study. The results of the interventional test will not be used in clinical decision making for the participant. Receives: Diagnostic Test: Thromboelastography (TEG 6S) |
What is being measured
The primary outcome is the main question the study is designed to answer.
TEG 6s viscoelastic measurement, angle, in pediatric surgical patients
To validate the TEG 6S measurement values in pediatric patients by comparing its viscoelastic values with those existing published reference ranges
Measured: Day 1, sample drawn at the time of clinical IV placement and evaluated within 1-4 hours of collection
TEG 6s viscoelastic measurements, R time, in pediatric surgical patients
To validate the TEG 6S measurement values in pediatric patients by comparing its viscoelastic values with those existing published reference ranges
Measured: Day 1, sample drawn at the time of clinical IV placement and evaluated within 1-4 hours of collection
TEG 6s viscoelastic measurement, maximum amplitude, in pediatric surgical patients
To validate the TEG 6S measurement values in pediatric patients by comparing its viscoelastic values with those existing published reference ranges
Measured: Day 1, sample drawn at the time of clinical IV placement and evaluated within 1-4 hours of collection
TEG 6s viscoelastic measurement, lysis at 30 minutes, in pediatric surgical patients
To validate the TEG 6S measurement values in pediatric patients by comparing its viscoelastic values with those existing published reference ranges
Measured: Day 1, sample drawn at the time of clinical IV placement and evaluated within 1-4 hours of collection
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 May 2023
- Study start11 Sep 2023
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CoagulopathyStudies of the same condition, open and under way.
- More trials run by Indiana UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 125 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Indiana University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Matthew Landman, Indiana University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05874843
- Sponsor's protocol ID
- 18124
- Status last verified
- Aug 2026
- First submitted
- 25 Apr 2023
- Last updated
- 4 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 4 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Validation of Point-of-care Thromboelastography (TEG 6s) in Pediatric Patients
- ClinicalTrials.gov ID
- NCT05874843
- Acronym / sponsor ID
- 18124
- Conditions
- Coagulopathy
- Keywords
- thromboelastography
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 125 participants (estimated)
- Lead sponsor
- Indiana UniversityUniversity, hospital or other
- Study start
- 11 Sep 2023 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 25 May 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to learn about the performance of the TEG6s in normal pediatric patients. The main questions it aims to answer are: What are the normal TEG 6S lab results in normal pediatric patients and how do they compare to existing published reference ranges. Participants and their guardians will be asked to submit a small amount of blood at the beginning of an elective operation for analysis in the TEG 6s machine.
Detailed description
Trauma is the leading cause of death in children. Researchers, starting with Trunkey et al., have described three general time points of mortality after trauma - in the field, early secondary to hemorrhage and late due to infectious complications. Early mortality after trauma is specifically linked to hemorrhage. Trauma-induced coagulopathy is a multifactorial phenomenon present after trauma in both children and adults that can worsen hemorrhage and ultimately lead to increased mortality. Classical laboratory measurements of the coagulation pathway (PT, PTT, INR, fibrinogen, platelet count) have shown derangement after trauma and are correlated with mortality. However, these traditional tests of coagulation function take time to run as they are drawn and sent to a laboratory for evaluation and therefore provide a delayed snapshot of a potentially evolving coagulopathy scenario. Adult trauma centers have increasingly incorporated viscoelastic measures of the coagulation cascade to evaluate for and subsequently treat trauma-induced coagulopathy. One such test is thromboelastography (TEG) which is a whole blood assay that assesses functional clot kinetics and stability. It provides information on how various hemostatic factors, including coagulation factors, platelets, and fibrinogen, contribute to the clot. A 2016 randomized-controlled trial in adult trauma patients who met criteria for the institutions massive transfusion protocol were randomized to transfusion guided by TEG or by conventional measure of coagulopathy. The authors found increased survival in the TEG group as well as less transfusion of platelets and fresh frozen plasma.
TEG assesses the clot rate, clot strength, and clot stability, which then assists the clinician in choosing appropriate blood component therapy. The American College of Surgeons Trauma Quality Improvement Program recommends the use of thromboelastography when patients are at risk for trauma-induced coagulopathy. Visicoeslastic evaluation of the coagulation pathway has become the standard of care in adult trauma patients to provide information on a patient's coagulation status, particularly when the patient is requiring multiple blood products. This allows the physician to deliver a targeted hemostatic resuscitation appropriate for the patient needs in real-time. This can result in a decrease of blood products and quicker reversal of the trauma induced coagulopathy.
Riley Hospital for Children at IU Health has a TEG 5000 machine (Haemonetics Corp.) which performs the coagulation tests needed to help guide the resuscitation of a critical trauma patient. While an improvement over previous tests (such as INR, platelet count, PTT), the TEG 5000 still takes 45-60 minutes to get the results needed to guide fluid/blood resuscitation, making the results outdated as the patient has potentially received multiple units of blood products and/or had additional bleeding during that time. The TEG 5000 machine also has very specific environmental, and preparation needs (i.e. flat surface which is not bumped; controlled pipetting (dropping) of blood products into machine as well as mixing of reagents) that is very difficult to do in a busy trauma bay/emergency department with a critical patient.
The TEG 6s assays are performed in a microfluidic cartridge which only requires a small amount of a patient's blood be transferred to the cartridge for analysis. The vibration frequency of the blood meniscus at which resonance occurs is used to create a clot dynamics tracing. The sample is drawn automatically into the testing chambers rather than requiring manual pipetting, leading to less user variability. This simpler operation provides results in 15-20 minutes, making the test more clinically useful in guiding transfusion therapy during active bleeding.
TEG 6s and TEG 5000 have been evaluated in adult patients with good agreement between the modalities. More specifically, the TEG 6s has been validated in adult trauma patients. However, few pediatric studies exist.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Pediatric Participants | Other | Diagnostic Test: Thromboelastography (TEG 6S)Pediatric surgery patients undergoing elective pediatric surgical cases under anesthesia will be invited to participate in this prospective laboratory test validation study. The results of the interventional test will not be used in clinical decision making for the participant. |
Who may qualify
- Ages
- 3 months to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (1 listed)
- -Patients less than 18 years of age undergoing elective pediatric surgical care in the operating room at Riley Hospital for Children
Key exclusion criteria (3 listed)
- Known disorder of coagulation pathway(s)
- Administration of medications that may alter the coagulation cascade
- Patients in foster care or wards of the court
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Thromboelastography (TEG 6S)The TEG 6s assays are performed in a microfluidic cartridge which only requires a small amount of a patient's blood be transferred to the cartridge for analysis. The vibration frequency of the blood meniscus at which resonance occurs is used to create a clot dynamics tracing. | Diagnostic test | Pediatric Participants |
Primary outcome
TEG 6s viscoelastic measurement, angle, in pediatric surgical patients
Time frame: Day 1, sample drawn at the time of clinical IV placement and evaluated within 1-4 hours of collection
To validate the TEG 6S measurement values in pediatric patients by comparing its viscoelastic values with those existing published reference ranges
TEG 6s viscoelastic measurements, R time, in pediatric surgical patients
Time frame: Day 1, sample drawn at the time of clinical IV placement and evaluated within 1-4 hours of collection
To validate the TEG 6S measurement values in pediatric patients by comparing its viscoelastic values with those existing published reference ranges
TEG 6s viscoelastic measurement, maximum amplitude, in pediatric surgical patients
Time frame: Day 1, sample drawn at the time of clinical IV placement and evaluated within 1-4 hours of collection
To validate the TEG 6S measurement values in pediatric patients by comparing its viscoelastic values with those existing published reference ranges
TEG 6s viscoelastic measurement, lysis at 30 minutes, in pediatric surgical patients
Time frame: Day 1, sample drawn at the time of clinical IV placement and evaluated within 1-4 hours of collection
To validate the TEG 6S measurement values in pediatric patients by comparing its viscoelastic values with those existing published reference ranges
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Aug 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Coagulopathy
RecruitingObservational study
A Study in Children and, Adults With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Treated With Adzynma
Thrombotic Thrombocytopenic Purpura (TTP)
RecruitingPhase 1/2
Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)
Hereditary Hemorrhagic Telangiectasia (HHT), Osler Weber Rendu Disease
RecruitingObservational study
The CACHE Study: Coronary Artery Care in HaEmophilia
Haemophilia, Cardiovascular Diseases
Active, not recruitingObservational study
An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment
Von Willebrand Disease, Type 3
RecruitingPhase 2
A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)
Primary Immune Thrombocytopenia (ITP), Primary Evans Syndrome (ES)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Thromboelastography (TEG 6S) in people with Coagulopathy, run by Indiana University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 4 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Matthew Landman, MD, MPH (317-944-4681, landman@iu.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
TEG 6s viscoelastic measurement, angle, in pediatric surgical patients (time frame: Day 1, sample drawn at the time of clinical IV placement and evaluated within 1-4 hours of collection). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Aug 2026.